Aimmune's peanut allergy immunotherapy clears European PhIII with flying colors, paving way for first US, EU therapeutic approval

Days after the FDA finally accepted the application to review its peanut allergy immunotherapy, Aimmune laid out positive pivotal study data from its European Phase III study on Monday, paving the way for an EMA marketing application by mid-2019.